SRP-1001

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameSRP-1001
Drug Alias NameARO-DUX4SRP-1001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionDouble homeobox protein 4 inhibitors
TargetsDouble homeobox protein 4
Therapy Area/IndicationsMuscular Dystrophy, Facioscapulohumeral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaThailandNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArrowhead Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncArrowhead Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Facioscapulohumeral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A